Tokyo Tape
Sign in
← Santen Pharmaceutical

Annual report

4536.TEDINET S100YDH1
Period2025-04-01 → 2026-03-31
Filed2026-06-18
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 156
MetricValuePeriodScopeSource row
Revenue¥291.6bn2025-04-01 → 2026-03-31Cons.Revenue IFRS
Revenue¥300.0bn2024-04-01 → 2025-03-31Cons.Revenue IFRS
Revenue¥302.0bn2023-04-01 → 2024-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥279.0bn2022-04-01 → 2023-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥266.3bn2021-04-01 → 2022-03-31vCons.Revenue IFRS (5-year summary)
Operating income¥47.8bn2025-04-01 → 2026-03-31Cons.Operating profit loss IFRS
Operating income¥46.9bn2024-04-01 → 2025-03-31Cons.Operating profit loss IFRS
Profit before tax¥47.4bn2025-04-01 → 2026-03-31Cons.Profit loss before tax IFRS
Profit before tax¥47.5bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS
Profit before tax¥29.9bn2023-04-01 → 2024-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥5.8bn2022-04-01 → 2023-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥35.6bn2021-04-01 → 2022-03-31vCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥37.4bn2025-04-01 → 2026-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥36.3bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥26.6bn2023-04-01 → 2024-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥14.9bn2022-04-01 → 2023-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥27.2bn2021-04-01 → 2022-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥37.6bn2025-04-01 → 2026-03-31Cons.Profit loss IFRS
Net income¥35.9bn2024-04-01 → 2025-03-31Cons.Profit loss IFRS
Total assets¥423.0bnat 2026-03-31Cons.Assets IFRS
Total assets¥409.3bnat 2025-03-31Cons.Assets IFRS
Total assets¥435.7bnat 2024-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥421.2bnat 2023-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥460.0bnat 2022-03-31vCons.Total assets IFRS (5-year summary)
Total liabilities¥127.0bnat 2026-03-31Cons.Liabilities IFRS
Total liabilities¥124.1bnat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥296.0bnat 2026-03-31Cons.Equity IFRS
Net assets / equity¥285.2bnat 2025-03-31Cons.Equity IFRS
Net assets / equity¥305.4bnat 2024-03-31vCons.Equity IFRS
Equity (owners)¥297.0bnat 2026-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥286.2bnat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥306.1bnat 2024-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥294.0bnat 2023-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥337.5bnat 2022-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥80.9bnat 2026-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥93.0bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥94.6bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Cash & equivalents¥57.9bnat 2023-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥83.0bnat 2022-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥43.5bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥60.9bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥72.6bn2023-04-01 → 2024-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥37.1bn2022-04-01 → 2023-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥46.0bn2021-04-01 → 2022-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥13.0bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.2bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥6.1bn2023-04-01 → 2024-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥26.8bn2022-04-01 → 2023-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥35.2bn2021-04-01 → 2022-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥49.3bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥53.3bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥34.0bn2023-04-01 → 2024-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥37.2bn2022-04-01 → 2023-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥5.6bn2021-04-01 → 2022-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥114.042025-04-01 → 2026-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥103.982024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥72.592023-04-01 → 2024-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-38.62022-04-01 → 2023-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥68.072021-04-01 → 2022-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥113.82025-04-01 → 2026-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥103.682024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.372023-04-01 → 2024-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-38.62022-04-01 → 2023-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥67.972021-04-01 → 2022-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥923.75at 2026-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥839.2at 2025-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥843.24at 2024-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥783.3at 2023-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥843.6at 2022-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio70.2%at 2026-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.9%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.2%at 2024-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.8%at 2023-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio73.4%at 2022-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE12.8%2025-04-01 → 2026-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE12.2%2024-04-01 → 2025-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.9%2023-04-01 → 2024-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE-4.7%2022-04-01 → 2023-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31vCons.Rate of return on equity IFRS (5-year summary)
Employees3,968at 2026-03-31Cons.Number of employees
Employees3,849at 2025-03-31Cons.Number of employees
Employees3,744at 2024-03-31vCons.Number of employees
Employees4,144at 2023-03-31vCons.Number of employees
Employees4,318at 2022-03-31vCons.Number of employees
Revenue¥171.8bn2025-04-01 → 2026-03-31StandaloneNet sales
Revenue¥188.1bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥195.2bn2023-04-01 → 2024-03-31vStandaloneNet sales (5-year summary)
Revenue¥196.6bn2022-04-01 → 2023-03-31vStandaloneNet sales (5-year summary)
Revenue¥190.8bn2021-04-01 → 2022-03-31vStandaloneNet sales (5-year summary)
Operating income¥20.5bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥23.4bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥22.0bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥26.2bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥31.3bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥27.1bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥22.5bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥22.4bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax¥25.1bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥15.8bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income¥17.8bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥18.7bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income−¥59.4bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥17.4bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥231.5bnat 2026-03-31StandaloneAssets
Total assets¥237.7bnat 2025-03-31StandaloneAssets
Total assets¥271.8bnat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥282.9bnat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥363.8bnat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥104.5bnat 2026-03-31StandaloneLiabilities
Total liabilities¥84.2bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥127.0bnat 2026-03-31StandaloneNet assets
Net assets / equity¥153.4bnat 2025-03-31StandaloneNet assets
Net assets / equity¥187.5bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥199.3bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥297.5bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥21.8bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥30.6bnat 2025-03-31StandaloneCash and deposits
EPS (basic)¥48.182025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥51.032024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥50.882023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-153.182022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥43.592021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥48.082025-04-01 → 2026-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥50.892024-04-01 → 2025-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥50.742023-04-01 → 2024-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥43.532021-04-01 → 2022-03-31vStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥382025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥362024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥332023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥322022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥322021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥394.39at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥449.15at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥515.75at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥529.72at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥742.3at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio54.8%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio64.5%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio68.9%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio70.3%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio81.7%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE11.3%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE10.5%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE9.7%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE-23.9%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE5.9%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued322,282,000at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued342,056,000at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued363,996,000at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued375,886,000at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued400,695,000at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees1,884at 2026-03-31StandaloneNumber of employees
Employees1,756at 2025-03-31StandaloneNumber of employees
Employees1,676at 2024-03-31vStandaloneNumber of employees
Employees1,807at 2023-03-31vStandaloneNumber of employees
Employees1,842at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 1,727
ItemContextValueUnit
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-28584000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember2128000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember2128000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember-36000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember-26492000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-979000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember122050000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember4816000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember4816000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember88000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember126954000000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember8312000000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember8864000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember1088000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember1171000000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember500000000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember330000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember6362000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember6473000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember25246000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember23926000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-06-18
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第114期（自　2025年４月１日　至　2026年３月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)参天製薬株式会社
Company name in english cover pageFilingDateInstantSANTEN PHARMACEUTICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長兼CEO　伊藤　毅
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市北区大深町４番20号
Telephone number address of registered headquarter cover pageFilingDateInstant06(4802)9322
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)Head of Accounting and Tax, Japan高木　宏典
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市北区大深町４番20号
Telephone number nearest place of contact cover pageFilingDateInstant06(4802)9322
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)Head of Accounting and Tax, Japan高木　宏典
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00949
Fund codeFilingDateInstant－
Security codeFilingDateInstant45360
Filer name in japaneseFilingDateInstant
Original text (Japanese)参天製薬株式会社
Filer name in englishFilingDateInstantSANTEN PHARMACEUTICAL CO., LTD.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2025-04-01

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2026-03-31pass rounding
balance sheet identitynon_consolidated 2025-03-31pass
balance sheet identitynon_consolidated 2026-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass